Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.35 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | UTRN | P46939 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929653 | 1.00 | PPARG (0.35) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4377288 | 0.94 | PPARG (0.37) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4375526 | 0.85 | PPARG (0.35) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4391942 | 0.85 | PPARG (0.35) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4382592 | 0.85 | PPARA (0.34) | PPARGPPARAPPARD | |
| SCHEMBL4388895 | 0.85 | PPARA (0.34) | PPARGPPARAPPARD | |
| SCHEMBL4391936 | 0.83 | PPARG (0.33) | PPARGPPARAPPARD | |
| SCHEMBL4375516 | 0.82 | PPARA (0.39) | PPARGPPARAPPARDMAPTTP53 | |
| SCHEMBL4384708 | 0.81 | PPARA (0.42) | PPARGPPARAPPARDSLC16A3SLC16A1 | |
| SCHEMBL4382001 | 0.81 | PPARA (0.42) | PPARGPPARAPPARDSLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-17 | — | — | US | disclosed |
| US-7259177-B2 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-20050101637-A1 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, ACADM | PPARG 80/4885PPARA 122/4885PPARD 132/4885 |
| US-20050101637-A1 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, PC, CPT1A | PPARG 99/4885PPARA 132/4885PPARD 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.